secwatch / observer
8-K filed May 19, 2025, 7:59 PM ET ticker VTVT CIK 0001641489
leadership confidence high sentiment neutral materiality 0.50

vTv Therapeutics appoints Michael Tung as CFO; reinitiates Phase 3 T1D trial

vTv Therapeutics Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Tung

executive vice president and chief financial officer
VTVT · vTv Therapeutics Inc.
Effective
2025-05-19
Filed
May 19, 2025, 7:59 PM ET
On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Tung was appointed as executive vice president and chief financial officer at vTv Therapeutics Inc..

Action
appointed
Role
executive vice president and chief financial officer
Exact text from the filing
On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.
View on SEC.gov

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR
accession 0001641489-25-000032
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.